Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Aim: To assess adherence and discontinuation of injectable glucagon-like peptide-1 receptor agonists (GLP-1 RA) at 12 and 24 months among adult type 2 diabetes mellitus (T2DM) patients in the United States initiating GLP-1 RA using the administrative claims-based database, Optum Clinformatics ® Data Mart 7.1. Methods: A retrospective study was conducted from 01/2009 to 12/2017. Patients were required to be continuously enrolled for 12 months prior to their first GLP-1 RA prescription. Proportion of days covered (PDC) from prescription claims ≥ 0.80 defined adherence. Discontinuation was defined as a ≥ 90-day gap from the last date of GLP-1 RA supply to the first date of subsequent prescription claim. Results: A total of 4791 T2DM patients had ≥ 1 and 3907 had ≥ 2 GLP-1 RA prescription claims. 50.9% and 47.4% of patients were adherent at 12 and 24 months, respectively. Adherence was significantly higher among patients on weekly vs daily doses (p< 0.001). Median time to discontinuation was 13 months. The discontinuation rate was 47.7% and 70.1% at 12 and 24 months, respectively, with differences at 24 months for age and dosing frequency (p< 0.001 for both). Conclusion: Over half of T2DM patients initiating GLP-1 RA were non-adherent and the majority (70.1%) discontinued therapy by 24 months. Reasons for non-adherence and discontinuation merit further research. Keywords: GLP-1 RA, adherence, discontinuation, United States
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“At the 12- and 24-month time points after the initiation of GLP-1 RA, the percentage of men who qualified as adherent exceeded that of women (adherence rate: 54.2% for men versus 48.4% for women at 12 months and 51.1% versus 44.6% at 24 months, respectively, p < 0.01). With regard to the same time intervals, males also presented with lower rates of discontinuation of treatment (p < 0.01) [90].”
From Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care (2022) · cites this paper as [90]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Roughly, 50% of persons with type 2 diabetes and 68% of those engaging in weight loss care who start a GLP-1RA are reported to discontinue treatment after 1 year.6,7”
From Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Males had lower treatment interruption rates and higher adherence rates than females, according to a retrospective study that looked at GLP-1 RA adherence and interruption rates [90].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [90]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High and widely varying rates of GLP-1 RA discontinuation at 1 year have been reported, ranging from 37% to 81%.20,21,22,23,24”
From Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity (2025) · cites this paper as [21]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In real-world settings, up to half of those who initiate treatment with a GLP-1 receptor agonist have discontinued treatment after one year.14, 15, 16, 17”
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 4×
“10 In the SUSTAIN6 trial, 22.6% of patients on semaglutide prematurely discontinued therapy during the 24-month trial period.”
InfluentialSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“29 Yet, in this real-world study, 70.1% of patients who initiated GLP-1 RA therapy discontinued therapy within 24 months.”
InfluentialGrundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012
Menke, A., Casagrande, S., Geiss, L., & Cowie, C. C. (2015) · JAMA · doi:10.1001/jama.2015.10029 · Cited by 2,362
Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Ho, P. M., Rumsfeld, J. S., Masoudi, F. A., McClure, D. L., Plomondon, M. E., Steiner, J. F., & Magid, D. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1836 · Cited by 1,135
Methods for evaluation of medication adherence and persistence using automated databases
Andrade, S. E., Kahler, K. H., Frech, F., & Chan, K. A. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1230 · Cited by 1,079
Cited by
Cusi, K., Abdelmalek, M. F., Apovian, C. M., Balapattabi, K., Bannuru, R. R., Barb, D., Bardsley, J. K., Beverly, E. A., Corbin, K. D., ElSayed, N. A., et al. (2025) · Diabetes Care · doi:10.2337/dci24-0094 · Cited by 332
Rodriguez, P. J., Zhang, V., Gratzl, S., Do, D., Goodwin Cartwright, B., Baker, C., Gluckman, T. J., Stucky, N., & Emanuel, E. J. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.57349 · Cited by 374
Jensen, S. B. K., Blond, M. B., Sandsdal, R. M., Olsen, L. M., Juhl, C. R., Lundgren, J. R., Janus, C., Stallknecht, B. M., Holst, J. J., Madsbad, S., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102475 · Cited by 207
Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16364 · Cited by 207
Rentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030454 · Cited by 140
Berg, S., Stickle, H., Rose, S. J., & Nemec, E. C. (2025) · Obesity Reviews · doi:10.1111/obr.13929 · Cited by 111
Polonsky, W. H., ARORA, R., Faurby, M. D., Fernandes, J. D. D. R., & Liebl, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01189-6 · Cited by 99
Malik, M. E., Falkentoft, A. C., Jensen, J., Zahir, D., Parveen, S., Alhakak, A., Andersson, C., Petrie, M. C., Sattar, N., McMurray, J. J. V., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100617 · Cited by 67
Basal weekly insulins: the way of the future!
Rosenstock, J., & Prato, S. D. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154924 · Cited by 76
Ramsey, D. J., Makwana, B., Dani, S. S., Patel, M., Panchal, K., Shah, J., Khadke, S., Kumar, A., Patel, T., Kosiborod, M. N., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.26321 · Cited by 63
Management of metabolic-associated fatty liver disease: The diabetology perspective
Jeeyavudeen, M. S., Khan, S. K., Fouda, S., & Pappachan, J. M. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i1.126 · Cited by 54
Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
Piccini, S., Favacchio, G., Panico, C., Morenghi, E., Folli, F., Mazziotti, G., Lania, A. G., & Mirani, M. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01800-z · Cited by 49
GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2192865 · Cited by 56
Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity
Hwang, J. H., Laiteerapong, N., Huang, E. S., Mozaffarian, D., Fendrick, A. M., & Kim, D. D. (2025) · JAMA Health Forum · doi:10.1001/jamahealthforum.2025.0905 · Cited by 43
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70059 · Cited by 56
Projecting the 30-year burden of obstructive sleep apnoea in the USA: a prospective modelling study
Boers, E., Barrett, M., Benjafield, A., Barnet, J. H., Ravelo, L. A., Kaye, L., Cistulli, P. A., Pépin, J., Armitstead, J. P., Sterling, K. L., et al. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00243-7 · Cited by 56
Lassen, M. C. H., Johansen, N. D., Modin, D., Catarig, A., Vistisen, B. K., Amadid, H., Zimmermann, E., Gislason, G., & Biering‐Sørensen, T. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15872 · Cited by 40
Lavu, M. S., Porto, J. R., Hecht, C. J., Kaelber, D. C., Sculco, P. K., Heckmann, N. D., & Kamath, A. F. (2024) · The Journal of Arthroplasty · doi:10.1016/j.arth.2024.06.008 · Cited by 46
Alhindi, Y., & Avery, A. (2022) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2022.100944 · Cited by 37
Furth, S. L., Colhoun, H. M., Kanbay, M., Kukla, A., Lim, L., MacLaughlin, H. L., Navaneethan, S. D., Shroff, R. C., Stenvinkel, P., Cheung, M., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.09.019 · Cited by 52
Porto, J. R., Lavu, M. S., Hecht, C. J., Kaelber, D. C., Sculco, P. K., Heckmann, N. D., & Kamath, A. F. (2025) · Orthopaedic Journal of Sports Medicine · doi:10.1177/23259671241297157 · Cited by 38
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
“After 24 months of follow-up, 68.2% of individuals less than 65 years old had discontinued GLP-1RAs, with the proportion rising to 75.3% for those 65–74 years old and 82.6% for those 75 or older (116).”
InfluentialJarade, C., Zolotarova, T., Moiz, A., & Eisenberg, M. J. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102789 · Cited by 32
Kunutsor, S. K., & Seidu, S. (2025) · Drugs · doi:10.1007/s40265-025-02263-0 · Cited by 44
Guan, H.-P., & Xiong, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1043828 · Cited by 30
Tang, A. S. P., Hsu, J. T. Y., Chong, S. K. S., Quek, J., Shek, G., Sulaimi, F., Chan, K. E., Anand, V. V., Chong, B., Mehta, A., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02840-3 · Cited by 29
Smits, M. M., & Holst, J. J. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3699 · Cited by 25
Wright, E. E., Roberts, G. J., Chuang, J. S., Nabutovsky, Y., Virdi, N., & Miller, E. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0015 · Cited by 22
“6,42,43 A recent investigation by Weiss et al. observed a discontinuation rate of 70.1% at 24 months.”
InfluentialRabbani, N., & Thornalley, P. J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111905 · Cited by 25
DeRemer, C. E., Vouri, S. M., Guo, J. S., Donahoo, W. T., Winterstein, A. G., & Shao, H. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107972 · Cited by 22
Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists
Jensen, E., Israelsen, M. E., & Krag, A. A. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000561 · Cited by 25
Puttarajappa, C. M., Smith, K. J., Ahmed, B. H., Bernardi, K., Lavenburg, L.-M. U., Hoffman, W., & Molinari, M. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.07.024 · Cited by 20
Wu, J., Zhou, R., Zhang, Q., Zhang, Q., Qin, H., Ye, Z., Xu, Y., Feng, S., Shu, C., Shen, Y., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15383 · Cited by 18
Type 2 diabetes in children and adolescents: Challenges for treatment and potential solutions
Jia, I. L. J., Zampetti, S., Pozzilli, P., & Buzzetti, R. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111879 · Cited by 31
Jiménez, V., Sacristan, V., Jambrina, C., Jaén, M. L., Casana, E., MUÑOZ, S. A., Marcó, S., Molas, M., García, M., Grass, I., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.023 · Cited by 16
De Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Zhou, Q., Li, G., Hang, K., Li, J., Yang, D., & Wang, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061324-011832 · Cited by 16
Scragg, J., Koutoukidis, D. A., Dirksen, C., Heitmann, B. L., & Jebb, S. A. (2025) · Med · doi:10.1016/j.medj.2025.100805 · Cited by 16
Effect of Antidepressants on Glucagon-Like Peptide-1 Receptor Agonist-Related Weight Loss
Durell, N., Franks, R., Coon, S., Cowart, K., & Carris, N. W. (2022) · Journal of Pharmacy Technology · doi:10.1177/87551225221110850 · Cited by 15
GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
Migliorisi, G., Gabbiadini, R., Buono, A. D., Ferraris, M., Privitera, G., Petronio, L., Bertoli, P., Bezzio, C., & Armuzzi, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1610368 · Cited by 26
McGill, J. B., Hirsch, I. B., Parkin, C. G., Aleppo, G., Levy, C. J., & Gavin, J. R. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01569-8 · Cited by 28
Fernando, K., Bain, S. C., Holmes, P., Jones, P. N., & Patel, D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01116-9 · Cited by 18
Boye, K. S., Shinde, S., Kennedy-Martin, T., Robinson, S., & Thieu, V. T. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s328583 · Cited by 18
Boye, K. S., Shinde, S., Kennedy‐Martin, T., Robinson, S. J., & Thieu, V. T. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 14
Sawicka‐Gutaj, N., Gruszczyński, D., Nijakowski, K., Derwich-Rudowicz, A., Krenz, M., Kumar, A. A., Lu, P.-Y., & Ruchała, M. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02088-1 · Cited by 24
Brixner, D. I., Edelman, S. V., Sieradzan, R., & Gavin, J. R. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01598-3 · Cited by 16
Unmet Needs in the Treatment of Childhood Type 2 Diabetes: A Narrative Review
Tamborlane, W. V., & Shehadeh, N. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02642-7 · Cited by 12
Koufakis, T., Παπάνας, Ν., Zebekakis, P. E., & Kotsa, K. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1942843 · Cited by 13
GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults
Hsu, A. H.-C., Ramirez, P. T., Chang, Y.-H., Chiang, Y. C., Santía, M. C., Meschini, T., Mateo-Kubach, P., Suri, A., & Kamat, A. A. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.04.013 · Cited by 12
Scheen, A. J. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2279193 · Cited by 13
Ulrich, F. S., Napoli, N., Nielsen, M. F., & Burden, A. M. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70535 · Cited by 10
The ketogenic diet is not for everyone: contraindications, side effects, and drug interactions
Dyńka, D., Rodzeń, Ł., Rodzeń, M., Łojko, D., Karakuła‐Juchnowicz, H., Ede, G., Grzywacz, Ż., Antosik, K., Sethi, S., & Unwin, D. (2026) · Annals of Medicine · doi:10.1080/07853890.2025.2603016 · Cited by 16
Shahabi, N. A., Hosseini, Z., Aghamolaei, T., Behzad, A., Ghanbarnejad, A., & Dadipoor, S. (2023) · Qualitative Health Research · doi:10.1177/10497323231206964 · Cited by 16
Hirsch, I. B., Parkin, C. G., Cavaiola, T. S., & Bergenstal, R. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15883 · Cited by 8
Causes and consequences of discontinuation of GLP1RAs or tirzepatide
Ceriello, A., Prattichizzo, F., Abdullah, A. R. M. S., Grotta, R. L., Berra, C., McGowan, B. M., Jenkins, A., Cohen, N. D., Nauck, M. A., & Russo, G. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01258-5 · Cited by 23
Interrupting T-Cell Memory Ameliorates Exaggerated Metabolic Response to Weight Cycling
Garcia, J. N., Cottam, M. A., Rodriguez, A. S., Agha, A. F. H., Caslin, H. L., Winn, N. C., & Hasty, A. H. (2026) · Diabetes · doi:10.2337/db25-0605 · Cited by 12
Xie, Y., Choi, T., & Al-Aly, Z. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002150 · Cited by 8
“24 28 54 Because out- of-pocket drug costs are major reasons for stopping GLP-1RA treatment in the US, 55 reducing these financial barriers may help reduce the risk of interruptions and discontinuations.”
Waataja, J. J., Asp, A. J., & Billington, C. J. (2023) · Biomedicines · doi:10.3390/biomedicines11092452 · Cited by 11
Mingrone, G., & Rajagopalan, H. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111651 · Cited by 10
Continuous positive airway pressure is here to stay
Malhotra, A., & Pettus, J. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00469-1 · Cited by 8
Riehl-Tonn, V. J., Medak, K. D., Rampersad, C., MacPhee, A., & Harrison, T. G. (2024) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581241290317 · Cited by 12
von Arx, L., Rachman, J., Webb, J., Casey, C. S., Patel, A. A., Diomatari, C., Wood, R. P., & IDRIS, I. R. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14985 · Cited by 9
NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management?
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2024) · Peptides · doi:10.1016/j.peptides.2024.171256 · Cited by 9
Miller, K., Carson, E., Boothe, K., & Brown, B. (2025) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2025.102385 · Cited by 7
Zhou, L., Wei, A., Pan, C., Zhang, J., Hu, P., Li, X., Zhao, X., Hu, Y., He, B., Liu, Y., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09950-4 · Cited by 11
Klepser, N., Weber, E. S., Li, L., Fleischmann, K. E., Masharani, U. B., Park, M., Max, W. B., Yeboah, J., Hunink, M. G. M., & Ferket, B. S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16619 · Cited by 6
Nadgir, U. M., Ali, S. R., Gogate, J. P., Shaw, W. C., Antunes, J., & Fonseca, S. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-04017 · Cited by 8
Current and Future Pharmacological Interventions for Acquired Hypothalamic Obesity
Roth, C. L., Doelman-Oldenburger, N. J., & van Santen, H. M. (2026) · Drugs · doi:10.1007/s40265-025-02280-z · Cited by 7
Kwon, J., Thiara, D., & Watanabe, J. H. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2462100 · Cited by 7
Robinson, G. N., & Pickering, R. J. (2024) · Diabetology · doi:10.3390/diabetology5010006 · Cited by 6
Icodec: A Novel Once-Weekly Basal Insulin for Diabetes Management
Goldman, J. D., Triplitt, C. L., & Isaacs, D. M. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241287790 · Cited by 8
Napoli, M. D., Rouhi, A. D., Dumon, K. R., Castle, R., Williams, N. N., Baimas‐George, M. R., Kennealey, P. T., Nydam, T. L., & Choudhury, R. A. (2025) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2025.04.001 · Cited by 6
Lu, Y., Liu, Y., Totojani, T., Kim, C., Khera, R., Xu, H., Brush, J. E., Krumholz, H. M., & Abaluck, J. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.26013 · Cited by 8
Uzoigwe, C., Noone, J. M., Liang, Y. M., Ali, S. N., & Gamble, C. L. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01322-z · Cited by 5
Tackling obstructive sleep apnea with pharmacotherapeutics: expert guidance
Harding, C. D., Fuentes, A. L., & Malhotra, A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2365329 · Cited by 8
Rodriguez, P. J., Zhang, V., Gratzl, S., Do, D., Cartwright, B. M. G., Baker, C., Gluckman, T. J., Stucky, N. L., & Emanuel, E. J. (2024) · medRxiv · doi:10.1101/2024.07.26.24311058 · Cited by 5
Cozma, D. C., Văcărescu, C., & Stoicescu, C. I. (2025) · Biomedicines · doi:10.3390/biomedicines13123079 · Cited by 5
HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial
Guo, L., Sun, Z., Zhang, L., Qin, G., Li, Y., Chen, X., Xu, N., Su, X., Li, M. T., Sun, J., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.15622 · Cited by 5
Mulcahy, J., DeLaRosby, A., & Norwood, T. (2025) · Physical Therapy · doi:10.1093/ptj/pzaf061 · Cited by 8
Sidra, F. N. U., Agarwal, S., Pastor, P. L., Xie, D., Li, X., & Lingvay, I. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108925 · Cited by 6
Chronic Disease Self-Management
Straub, L., & Thekkekandam, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-29171-5_5 · Cited by 6
Armanious, A. J., Hunter, R.-M., Griffiths, K. R., Bowrey, H. E., Brown, R. M., & James, M. H. (2025) · Journal of Medical Internet Research · doi:10.2196/78391 · Cited by 5
Beke, G., Boros, A. M., Keserű, G. M., Krámos, B., Szalai, K., Gere, A., Vastag, M., Thán, M., Varga, B., Balázs, O., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02708 · Cited by 4
Heisey, H. D., Gregg, L. P., Verrico, C. D., Villareal, D. T., & Fletcher, T. L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70913 · Cited by 4
What Is the Role of Basal Weekly Insulin in Clinical Practice? The State of the Art
Argano, C., Priola, L., Manno, F., & Corrao, S. (2024) · Biomedicines · doi:10.3390/biomedicines12040900 · Cited by 5
Gavin, K. L., Amjad, R., Makris, V., & Neuner, J. M. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.12.1311 · Cited by 2
Burns, R. B., Jay, M. R., Thorndike, A. N., & Kanjee, Z. (2024) · Annals of Internal Medicine · doi:10.7326/annals-24-01740 · Cited by 2
“In observational data, real-world adherence to GLP-1RAs prescribed for diabetes was 65% at 1 year and 30% at 2 years; adherence was highest among those with lowest insurance copays (23, 24).”
Clarifying the real challenge: adherence, not efficacy, is the barrier to exercise as medicine
MacDonald, C., Bennekou, M., Midtgaard, J., Langberg, H., & Lieberman, D. E. (2025) · British Journal of Sports Medicine · doi:10.1136/bjsports-2025-110988 · Cited by 3
Treatment approaches for alcohol use disorder with metabolic dysfunction
Wagner, A. C., Jung, J., Pacher, P., & Lohoff, F. W. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108957 · Cited by 6
Factors contributing to non-persistence of glucagon-like peptide-1 agonists: a cross-sectional study
Liu, S., Wong, G., Mavi, P., Gysel, S. C., Burton, D., Monteiro, N., Durocher, D., Sharma, A. M., & Tsuyuki, R. T. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100674 · Cited by 4
Hanif, M., Nagarajan, J. S., Murphy, R., Sah, S., Ye, S., Perl, A., & Taub, C. C. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.02.016 · Cited by 4
Rabbani, S. A., Saini, M., El-Tanani, M. E.-T., Kumar, R., Matalka, I. I., El‐Tanani, Y., Sharma, S., & Rizzo, M. (2026) · Pharmaceuticals · doi:10.3390/ph19050732 · Cited by 5
Almazan, E., Choi, J., Kamath, T., Nguyen, V. H., Przybyszewski, E. M., Song, J., Carroll, A., Michta, M., Simon, T. G., & Chung, R. T. (2026) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000004048 · Cited by 2
GLP-1 Receptor Agonists in Periodontology: Mechanisms, Clinical Evidence, and Implications for Care
Șufaru, I.-G., Vasiliu, B. C., Hăncianu, M., Stratul, Ş., Tatarciuc, M., Iovan, G., Tatarciuc, D., Rudnic, I., Hanu, D., Paduraru, S., et al. (2026) · Biomolecules · doi:10.3390/biom16060857 · Cited by 6
Modern-Day Management of the Dysglycemic Continuum: An Expert Viewpoint from the Arabian Gulf
Alessa, T., Alawadi, F., Alkaabi, J., Al-Mamari, A., Al‐Ozairi, E., Alromaihi, D., Elhadd, T. A., Gunaid, A. A., Hassanein, M. M., Jayyousi, A., et al. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s491591 · Cited by 3
Tapper, E. B., Ryan, T., Zeng, N., Carter, R., Winer-Jones, J. P., Bonafede, M., & Kim, Y. (2025) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2024-0223 · Cited by 2
Rai, S. K., Patil, R. I., Ali, S., Kumar, R., Khan, M. I., Panwar, A., Reddy, S., Ahsan, M., Iyer, S. S., & Kumar, A. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00540 · Cited by 2
Alexander, G. C., Xu, Y., Xiao, X., Lewis, S. V., Zeger, S., & Mehta, H. B. (2026) · Obesity · doi:10.1002/oby.70076 · Cited by 1
Olowo‐Oribi, B. A., & Salway, R. J. (2025) · Academic Emergency Medicine · doi:10.1111/acem.70088 · Cited by 3
Kim, Y., Zeng, N., Winer-Jones, J. P., Bonafede, M., Lobo, F., O'Donnell, J., & Ryan, T. (2025) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s546841 · Cited by 2
Metadata
- Authors
- Weiss, T., Carr, R. D., Pal, S., Yang, L., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- MSD (UK) Limited (United Kingdom) (GB)
- Corresponding author
- Weiss, Tracey
- ORCID
- Venue
- Patient Preference and Adherence
- Publisher
- Informa UK Limited
- Published
- 2020-11
- Volume
- Volume 14
- Pages
- 2337-2345
- ISSN
- 1177-889X (ISSN-L)
- PMC
- PMC7708309
- OpenAlex
- W3109831190
- Cited by
- 126
- References
- 37
- Citations by year
- 2026: 34 · 2025: 39 · 2024: 28 · 2023: 13 · 2022: 7 · 2021: 5
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Patient Preference and Adherence (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, medication adherence, treatment discontinuation, proportion of days covered, dosing frequency, real-world evidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.